Results 171 to 180 of about 100,614 (290)
Gemcitabine and rapamycin-loaded mixed polymeric thermogel for metastatic pancreatic cancer therapy
Seo Yeon Kim +14 more
openalex +1 more source
ABSTRACT Introduction Endoscopic retrograde cholangiopancreaticography (ERCP) is the gold standard for bile duct drainage in non‐resectable malignant distal bile duct obstruction with jaundice in pancreaticobiliary and duodenal neoplasia. Failed ERCP is either followed by endoscopic ultrasound‐guided biliary drainage (EUS‐BD) or percutaneous ...
Thomas Roland Heiduk +6 more
wiley +1 more source
Multimodal treatment of radiation-associated laryngeal angiosarcoma: A case report and literature review. [PDF]
Pan Y, Liu X, Nie X, Wang S, Zeng W.
europepmc +1 more source
ABSTRACT A 60‐year‐old female with abdominal pain and nausea was diagnosed with gallbladder cancer (cT3aN2M1, cStage IVB). Distant metastases had disappeared after 10 courses of chemotherapy, followed by conversion surgery consisting of subtotal stomach‐preserving pancreaticoduodenectomy, partial hepatectomy, and dissection of para‐aortic and regional ...
Yuki Ito +9 more
wiley +1 more source
A serum-derived 3D tumor model platform for personalized prediction and monitoring of chemotherapeutic response in pancreatic ductal adenocarcinoma. [PDF]
Cherradi S +4 more
europepmc +1 more source
CO32 Predictors of Overall Survival (OS) and Time to Next Treatment (TTNT) in Real-World Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Patients Who Received First-Line (1L) Folfirinox (FFX) or Gemcitabine + Nab-paclitaxel (GnP) [PDF]
Syvart Dennen +3 more
openalex +1 more source
The review provides a comprehensive analysis of microbiome‐mediated oncogenic mechanisms in various cancers, emphasizing the unique therapeutic strategies facilitated by nanotechnology. It aims to fill this gap by systematically reviewing nanotechnology‐driven strategies for microbiome elimination, with a focus on their ability to improve the cold TME ...
Yumei Gan, Yan Zhang, Xia Dong, Feng Lv
wiley +1 more source
Targeting E2F8 sensitizes gemcitabine-resistant gallbladder cancer to PARP inhibitors by disrupting RRM2-driven DNA repair. [PDF]
Ni X +8 more
europepmc +1 more source

